Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.

ABSTRACT:

Purpose

The aim of this study is to investigate the effect of hepatic or renal impairment on the pharmacokinetics of a single 130-mg evacetrapib dose.

Methods

Two open-label, parallel-design studies in males and females with normal hepatic function or Child-Pugh mild, moderate, or severe hepatic impairment, or with normal renal function or severe renal impairment. Non-compartmental pharmacokinetic parameters were estimated from plasma concentration-time data. Evacetrapib safety and tolerability were assessed.

Results

Pharmacokinetic parameter estimates were comparable between controls and mildly hepatically impaired subjects. Geometric mean area under the concentration-time curve (AUC) was greater, half-life (t1/2) was longer, and maximum concentration (Cmax) was lowe

SUBMITTER: Small DS 

PROVIDER: S-EPMC4834099 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature